Although consensus was not reached on the World Health Organization’s pandemic agreement, the World Health Assembly recognized the progress made by member states to develop a pandemic agreement and to strengthen International Health Regulations (IHR, 2005) during the 77th World Health Assembly meeting held May 27 to June 1 in Geneva.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Astellas, Eisai, Genovate, Henlius, SN Bioscience, Telix.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Astrazeneca, HLB, I-Mab, Inmexd, Innovent, Neuren, Onconic, Opthea, Otsuka, Rege, Telix, Tyligand,
Biopharma happenings in Asia-Pacific including deals and partnerships, grants, preclinical data and other news in brief: Anocca, Bio-Thera, Biontech, Daiichi Sankyo, Eisai, Glyconex, Grit Biotechnology, Huidagene Medilink, Precisemab, Quangang Revolka, Shinobi, Stada Arzneimittel, Synthego.
While there was much talk about the vast potential of artificial intelligence (AI) during one of the world’s largest research cancer conferences, antibody-drug conjugates (ADCs) continued to grab the lion’s share of attention as Corbus Pharmaceuticals Holdings Inc. and Takeda Pharmaceutical Co. Ltd. released new and positive data.
Although details are scant, Akeso Pharmaceuticals Inc. reported that its PD-1/VEGF bispecific antibody, ivonescimab (AK-112), demonstrated statistically significant superiority as a first-line therapy for PD-L1-positive non-small-cell lung cancer (NSCLC) compared to Merck and Co. Inc.’s Keytruda (pembrolizumab).
South Korea’s Celltrion Inc. secured May 22 the European Commission’s go-ahead for Omlyclo (CT-P39) to be the first biosimilar to Genentech Inc./Novartis AG’s Xolair (omalizumab) in Europe for three of its major indications.
Cambridge, U.K.-based Astrazeneca plc is looking to Asia, specifically China and Singapore, to build an innovative cancer-focused pipeline filled with antibody-drug conjugates (ADC), monoclonal antibodies (MAbs) and cell therapies.
RSS
